Mide Kanserli Hastalarda Siklin D1 (G870A) Gen Polimorfizminin Araştırılması

Amaç: Mide kanseri Türkiye’de kadın ve erkeklerde 2. en sık görülen kanserdir. Etyolojide çevresel ve bireysel pek çok etken suçlanırken genetik faktörler ile ilgili de pek çok inceleme yapılmıştır. Hücre siklusunda önemli rol oynayan siklinler üzerinde durulmuş, özellikle siklin D1 gen polimorfizminin bazı kanserlerin gelişiminde rolü gösterilmiştir. Bu çalışmada da toplumumuzda siklin D1 gen polimorfizmi ile mide kanseri arasındaki ilişki araştırmayı amaçladık. Gereç ve Yöntem: Çalışma Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi Genel Cerrahi kliniğine 2005–2010 yılları arasında başvuran mide kanseri tanısı konmuş 57 hasta ve sağlıklı bireylerin oluşturduğu 59 kişilik kontrol grubu ile yapıldı. Uludağ Üniversitesi Tıp Fakültesi Tıbbi Genetik Ana Bilim Dalı’nda PCR-RFLP yöntemi ile genotip tayini yapıldı. Bulgular: Hasta grubunda GG genotipi 16 (%28), AG genotipi 28 (%49) ve AA genotipi 13 (%23) olarak saptandı. Kontrol grubunda GG genotipi 11 (%19), AG genotipi 31 (%54) ve AA genotipi 17 (%29) olarak bulundu. GG, AG ve AA genotipleri açısından hasta grubu ile kontrol grubu karşılaştırıldığında istatistiksel olarak anlamlı bir fark saptanmadı. Hasta grubunda G alleli 60 (%53), A alleli 54 (%47), kontrol grubunda ise G alleli 51 (%45), A alleli 66 (%55) olarak bulundu. Sonuç: Bu çalışma bildiğimiz kadarıyla Türk toplumunda mide kanseri ile siklin D1 gen polimorfizmini araştıran ilk çalışmadır. Elde ettiğimiz sonuçlar hasta ve kontrol gruplarımızın temsil ettiği toplum kesitinde mide kanseri ile siklin D1 gen polimorfizmi arasında bir ilişki olmadığını göstermektedir

-

Objectives: Gastric carcinoma is the second most common cancer in both man and woman in Turkey. Many environmental and individual etiological factors have been investigated including genetic factors. Cyclins which have an important role in cell cycle have been studied, particularly cyclin D1 gene polymorphism has been found to have a role in some cancers. In this study, association between cyclin D1 gene polymorphism and gastric carcinoma was searched in our community. Materials and Methods: Fifty-eight gastric carcinoma patients who had been admitted at Bursa Yüksek İhtisas Hospital General Surgery Department between 2005 and 2010 and 59 healthy individuals have been included in the study. Samples have been subjected to genetic analysis by PCR-RFLP method in Medical Genetics Department laboratory at Uludag University. Results: GG genotype was found in 16 (28%), AG genotype in 28 (49%), AA genotype in 13 (%23) in patient group. In control group, numbers was 11 (19%), 31 (54%) and 17 (29%) respectively. The difference of GG, AG and AA genotypes between patient and control groups was not statistically significant. G allele was found 60 (53%) and an allele 54 (47%) in patient group and 51 (45%), and 66 (55%) in control group. Conclusion: Our knowledge, this study is the first to evaluate the relation between gastric carcinoma and cyclin D1 polymorphism in Turkish population. Our results show that there is no any association between gastric carcinoma and cyclin D1 polymorphism in the community which is represented by our study and control groups
Keywords:

-,

___

  • Winawer SJ. Gastric cancer: Worldwide burden and prevention opportunities. Chin J Dig Dis. 2005;6(3):107-9.
  • Tuncer AM. Türkiye’de Kanser Kontrolü. Ankara: Onur Matbaacılık, 2007.
  • Stadtländer CT, Waterbor JW. Molecular epidemiology pathogenesis and prevention of gastric cancer. Carcinogenesis. 1999; 20(12):2195-8.
  • Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52(24):6735-40.
  • Correa P, Piazuelo MB, Camargo MC. Future of gastric cancer prevention. Gastric Cancer. 2004;7(1):9-16.
  • Jia A, Gong J, Li Y, et al. GG genotype of cyclin D1 G870A polymorphism is associated with non-cardiac gastric cancer in a high-risk region of China. Scand J Gastroenterol. 2008;43(11):1353-9.
  • Massagué J. G1 cell-cycle control and cancer. Nature. 2004;432(7015):298-306.
  • Arber N, Gammon MD, Hibshoosh H, et al. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol. 1999; 30(9):1087-92.
  • Oda K, Okabayashi T, Kataoka M, et al. Evaluation of cyclin D1 mRNA expression in gastric and colorectal cancers. Res Commun Mol Pathol Pharmacol. 1999;105(3):237-52.
  • Knudsen KE, Alan Diehl J, Haiman CA, et al. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006; 25(11):1620-8.
  • Loh M, Koh KX, Yeo BH, et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer. 2009;45(14):2562-8.
  • Liu W, Zhu E, Wang R, et al. Cyclin D1 gene polymorphism, A870G, is associated with an increased risk of salivary gland tumors in the Chinese population. Cancer Epidemiol. 2011; 35(4):e12-7.
  • Kang S, Kim JW, Park NH, et al. Cyclin D1 polymorphism and the risk of endometrial cancer. Gynecol Oncol. 2005; 97(2):431-5.
  • Yu J, Habuchi T, Tsuchiya N, et al. Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma. J Urol. 2004; 172(6 Pt 1):2410-3.
  • Hong Y, Eu KW, Seow-Choen F, et al. GG genotype of cyclin D1 G870A polymorphism is associated with increased risk and advanced colorectal cancer in patients in Singapore. Eur J Cancer. 2005;41(7):1037-44.
  • Krippl P, Langsenlehner U, Renner W, et al. The 870G > A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat. 2003; 82(3):165-8.
  • Grieu F, Malaney S, Ward R, et al. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res. 2003;23(5b):4257-9.
  • Yu C, Lu W, Tan W, et al. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2003;12(2):176.
  • Sanyal S, Festa F, Sakano S, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25(5):729-34.
  • Cortessis VK, Siegmund K, Xue S, et al. A case–control study of cyclin D1 CCND1 870A > G polymorphism and bladder cancer. Carcinogenesis. 2003;24(10):1645-50.
  • Zhang YJ, Chen SY, Chen CJ, et al. Polymorphisms in cyclin D1 gene and hepatocellular carcinoma. Mol Carcinog. 2002;33(2):125-9.
  • Geddert H, Kiel S, Zotz RB, et al. Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol. 2005;131(12):803-8.
  • Zhang J, Li Y, Wang R, et al. Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer 2003;105(2):281-4.
  • Akkiz H, Bayram S, Bekar A, et al. Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol. 2010; 34(3):298- 302.
  • Yaylim-Eraltan I, Arikan S, Yildiz Y, et al. The influence of cyclin D1 A870G polymorphism on colorectal cancer risk and prognosis in a Turkish population. Anticancer Res. 2010;30(7):2875-80.
  • Stocker G, Ott K, Henningsen N, et al.CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur J Cancer. 2009;45(18):3326-35.